Biopharma · FDA Approvals · Stock
SLS SELLAS Life Sciences
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antig…
Assets on file: galinpepimut-S, SLS009
Catalyst calendar
Dated catalysts for SLS, including recently decided ones.
Recent first-hand events
Every first-hand event for SLS, newest first.
SLSSELLAS Life SciencesSELLAS: SLS009 Phase 2 AML topline data expected Q4 2026
The company announced that 28 of 80 planned patients have been enrolled in the Phase 2 trial of SLS009 in newly diagnosed first-line AML and that topline data are expected in Q4 2026. This establishes the next clinical readout milestone for the CDK9 inhibitor program.
SLSSELLAS Life SciencesSELLAS: REGAL Phase 3 GPS AML trial reaches 78/80 events
The REGAL Phase 3 trial of GPS in AML has reached 78 of the 80 pre-specified events needed for final analysis. The company remains blinded to outcomes and will conduct the final analysis once the 80th event occurs, triggering database lock and topline disclosure.
Peers by market cap
Companies in the same sector closest to SLS in market value.
XNCRXencorMarket cap $924.8M · 1 tracked drug · 1 upcoming catalyst
OPKOPKO HealthMarket cap $926.1M · 1 tracked drug · 2 upcoming catalysts
ABUSArbutus BiopharmaMarket cap $872.4M · 1 tracked drug · 1 upcoming catalyst
MGTXMeiraGTxMarket cap $941.3M · 1 tracked drug
CMPXCompass TherapeuticsMarket cap $943.7M · 1 tracked drug · 4 upcoming catalysts
AMPHAmphastarMarket cap $944.6M · 1 tracked drug
CGEMCullinanMarket cap $860.7M · 3 tracked drugs · 5 upcoming catalysts
TBPHTheravance BiopharmaMarket cap $855.8M · 2 tracked drugs